Trial reportClinical nuclear medicine2012
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
Trial report in Clinical nuclear medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 138 citations in OpenAlex.
- A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [Molecular imaging and biology · 2017Trial
- Diagnostic performance ofFrontiers in oncology · 2026Article
- Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.Frontiers in oncology · 2026Article
- Review
- Application of next-generation imaging in biochemically recurrent prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- Hybrid magnetic resonance and PET imaging for prostate cancer recurrence.Current opinion in oncology · 2023Review
- Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?Frontiers in medicine · 2023Review
- With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.Nutrients · 2022Review
- Review
- Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells.Antioxidants (Basel, Switzerland) · 2022Article
- The value ofFrontiers in bioengineering and biotechnology · 2022Article
- Comparison of Bone Metastases betweenContrast media & molecular imaging · 2022Article
- FDG PET/CT - not PSMA trendy, but available, comfortable, and complementary.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Optimizing the diagnosis and management of ductal prostate cancer.Nature reviews. Urology · 2021Review
- Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies.Frontiers in oncology · 2021Article
- Advanced Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI, and Radiomics.Frontiers in oncology · 2020Article
- Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.Theranostics · 2020Article
- Treatment Response Assessment of Skeletal Metastases in Prostate Cancer withNuclear medicine and molecular imaging · 2019Article
- Mechanochemical Disruption Suppresses Metastatic Phenotype and Pushes Prostate Cancer Cells toward Apoptosis.Molecular cancer research : MCR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeThis study aimed to perform a prospective evaluation of 18F-NaF and 18F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer and biochemical relapse.
methodsThirty-seven men with prostate-specific antigen (PSA) relapse (median, 3.2 ng/mL; range, 0.5-40.2 ng/mL) after definitive therapy for localized prostate cancer [26 radical prostatectomy (RP), 11 external beam radiation therapy] and negative conventional imaging underwent 18F-FDG and 18F-NaF PET/CT on 2 separate days within the same week. Studies were interpreted by 2 experienced radiologists in consensus for abnormal uptake suspicious for metastatic disease. The reference standard was a combination of imaging and clinical follow-up. Rank of PSA values for positive and negative PET/CT was compared using analysis of variance adjusting for primary therapy. Association between PSA and scan positivity in patients with RP was evaluated using Wilcoxon rank sum test.
resultsResult of the 18F-FDG PET/CT scan was positive for nodal disease in 2 patients. True-positive detection rate for occult osseous metastases by 18F-NaF PET/CT was 16.2%. Median PSA levels for positive versus negative PET/CT scans were 4.4 and 2.9 ng/mL, respectively, with the difference marginally significant in prostatectomized men (P=0.072). Percentages of patients with either 18F-NaF- or 18F-FDG-positive PET/CT in RP and external beam radiation therapy were 10% (n=10) and undefined (n=0) for a PSA of 2 ng/mL or less, 29% (n=7) and 50% (n=2) for PSA greater than 2 ng/mL but 4 ng/mL or less, 60% (n=5) and 40% (n=5) for PSA greater than 4 ng/mL but 10 ng/mL or less, and 25% (n=4) and 25% (n=4) for PSA greater than 10 ng/mL, respectively.
conclusionsIn biochemical relapse of prostate cancer, 18 F-NaF PET/CT is useful in the detection of occult osseous metastases, whereas the yield of 18F-FDG PET/CT is relatively limited. 18F-NaF PET/CT positivity tends to associate with increasing PSA level in prostatectomized men and may occur in lower PSA ranges than conventionally recognized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.